SCHEMBL5538015

SCHEMBL5538015

CN(Cc1ccc(OC(F)(F)F)cc1)C(=O)Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LSS P48449 1/20 0.51
SCN9A Q15858 1/20 0.48
SLC6A4 P31645 3/20 0.48
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HTT P42858 1/20 0.48
KDM4E B2RXH2 1/20 0.47
TSHR P16473 1/20 0.47
SERPINE1 P05121 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TEAD1 P28347 1/20 0.44
TEAD4 Q15561 1/20 0.44
TEAD2 Q15562 1/20 0.44
TEAD3 Q99594 1/20 0.44
EPHX2 P34913 2/20 0.44
NR1H4 Q96RI1 1/20 0.44
EPHX1 P07099 1/20 0.44
SLC6A2 P23975 2/20 0.43
HSP90AA1 P07900 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14562861 0.87 SERPINE1 (0.53) LSSSCN9ASLC6A4ALDH1A1SMN1; SMN2
SCHEMBL27629442 0.84 EPHX1 (0.50) LSSSCN9ASLC6A4ALDH1A1SMN1; SMN2
SCHEMBL27897594 0.81 SERPINE1 (0.48) LSSSCN9ASLC6A4ALDH1A1TSHR
SCHEMBL7390057 0.79 MTOR (0.55) LSSALDH1A1HTTKDM4EMEN1
SCHEMBL13074386 0.78 SLC6A4 (0.57) LSSSLC6A4ALDH1A1TSHRSERPINE1
SCHEMBL2056224 0.78 SLC6A4 (0.66) LSSSLC6A4ALDH1A1TSHRSLC6A2
SCHEMBL12039097 0.76 RIPK1 (0.58) ALDH1A1SMN1; SMN2HTTKMT2ANPC1
SCHEMBL5535914 0.76 GPBAR1 (0.46) LSSSLC6A4ALDH1A1SERPINE1MEN1
SCHEMBL1462002 0.75 NLRP3 (0.50) ALDH1A1SMN1; SMN2TSHRMEN1KMT2A
SCHEMBL13157801 0.75 SLC6A4 (0.54) LSSSCN9ASLC6A4ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-102532162-A 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2012-07-04 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LSS 2164/4885SCN9A 3612/4885SLC6A4 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.